| General Information | |
|---|---|
| ZINC ID | ZINC000043065016 |
| Molecular Weight (Da) | 407 |
| SMILES | Cc1noc(C)c1S(=O)(=O)N1CCc2c(nc(CC(C)(C)C)n2CC2CC2)C1 |
| Molecular Formula | C20N4O3S1 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 106.121 |
| HBA | 5 |
| HBD | 0 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 28 |
| LogP | 2.372 |
| Activity (Ki) in nM | 7.079 |
| Polar Surface Area (PSA) | 89.61 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | - |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | - |
| Plasma protein binding | 0.4947659 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 10 |
| Fraction csp3 | 0.7 |
| Ilogp | 3.13 |
| Xlogp3 | 2.71 |
| Wlogp | 3.72 |
| Mlogp | 1.51 |
| Silicos-it log p | 2.99 |
| Consensus log p | 2.81 |
| Esol log s | -3.94 |
| Esol solubility (mg/ml) | 4.71E-02 |
| Esol solubility (mol/l) | 1.16E-04 |
| Esol class | Soluble |
| Ali log s | -4.25 |
| Ali solubility (mg/ml) | 2.31E-02 |
| Ali solubility (mol/l) | 5.69E-05 |
| Ali class | Moderately |
| Silicos-it logsw | -5.17 |
| Silicos-it solubility (mg/ml) | 2.75E-03 |
| Silicos-it solubility (mol/l) | 6.76E-06 |
| Silicos-it class | Moderately soluble |
| Pgp substrate | |
| Log kp (cm/s) | -6.86 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 1 |
| Synthetic accessibility | 4.12 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -4.207 |
| Logd | 3.285 |
| Logp | 3.113 |
| F (20%) | 0.07 |
| F (30%) | 0.372 |
| Mdck | 2.48E-05 |
| Ppb | 0.9766 |
| Vdss | 1.16 |
| Fu | 0.0358 |
| Cyp1a2-inh | 0.043 |
| Cyp1a2-sub | 0.226 |
| Cyp2c19-inh | 0.909 |
| Cyp2c19-sub | 0.746 |
| Cl | 7.835 |
| T12 | 0.369 |
| H-ht | 0.976 |
| Dili | 0.978 |
| Roa | 0.401 |
| Fdamdd | 0.944 |
| Skinsen | 0.033 |
| Ec | 0.003 |
| Ei | 0.008 |
| Respiratory | 0.96 |
| Bcf | 1.594 |
| Igc50 | 3.697 |
| Lc50 | 5.395 |
| Lc50dm | 4.487 |
| Nr-ar | 0.008 |
| Nr-ar-lbd | 0.005 |
| Nr-ahr | 0.153 |
| Nr-aromatase | 0.764 |
| Nr-er | 0.062 |
| Nr-er-lbd | 0.144 |
| Nr-ppar-gamma | 0.475 |
| Sr-are | 0.71 |
| Sr-atad5 | 0.002 |
| Sr-hse | 0.008 |
| Sr-mmp | 0.064 |
| Sr-p53 | 0.008 |
| Vol | 398.571 |
| Dense | 1.019 |
| Flex | 20 |
| Nstereo | 0.3 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | 0 |
| Toxicophores | 0 |
| Qed | 1 |
| Synth | 0.761 |
| Fsp3 | 3.017 |
| Mce-18 | 0.7 |
| Natural product-likeness | 63.529 |
| Alarm nmr | -1.73 |
| Bms | 1 |
| Chelating | 0 |
| Pfizer | 0 |
| Gsk | Accepted |
| Goldentriangle | Rejected |